Immunovant, Inc.

IMVTNASDAQHealthcare● Active

$31.10

$-0.01(-0.03%)

Market Cap$6.4B

P/E Ratio—

52W High$36.285

52W Low$14.32

Avg Volume1.8M

Open$31.69

Beta0.79

Free Cash Flow Financials Revenue

Immunovant, Inc. (IMVT) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

IMVT · free cash flow · updated Jun 8, 2026

Core FCF metrics

IMVT · FCF · TTM · margin & CAGR

Free cash flow was −$407.3M for FY2026 (fiscal year ending 2026-03-31), down 8.1% year-over-year

FY2026 Free Cash Flow−$407.3M▼ -8.1% YoY

Trailing 12M (TTM)−$407.3Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

IMVT · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2026Latest−$407.3M(0M)−$407.3M▼ 8.1%—

FY2025−$375.9M(1M)−$376.6M▼ 75.5%—

FY2024−$214.2M(0M)−$214.6M▼ 13.9%—

FY2023−$188.2M(0M)−$188.4M▼ 77.1%—

FY2022−$106.1M(0M)−$106.4M▼ 27.3%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

IMVT · P/FCF · FCF yield · FCF per share

Immunovant, Inc. (IMVT) reported negative free cash flow of −$0.41B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2026 · 2026-03-31

Cash flow statement summary

IMVT · cash flow statement · operating / investing / financing

For FY2026, Immunovant, Inc. generated −$407.3M in operating cash flow and spent 0M in capital expenditures, yielding −$407.3M in free cash flow.

Operating Activities

−$407.3M

Cash from core business operations

2026-03-31

Investing Activities

−$0.0M

CapEx, acquisitions & investments

2026-03-31

Financing Activities

+$595.8M

Buybacks, dividends & debt

2026-03-31

FCF FormulaOperating CF (−$407.3M) − |CapEx| (0M) = FCF (−$407.3M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

IMVT vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Immunovant, Inc.YOU

IMVT

−$407.3M-8.1%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Immunovant, Inc. (IMVT) reported free cash flow of −$407.3M for FY2026 (fiscal year ending 2026-03-31), down 8.1% year-over-year.

Immunovant, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 9 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

IMVT free cash flow · 8 questions

Immunovant, Inc. free cash flow was −$407.3M for FY2026, down 8.1% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$407.3M.

IMVT free cash flowIMVT FCFIMVT FCF 2026IMVT free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Immunovant, Inc. · Immunovant, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026